Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid

John D. Imig, Xueying Zhao, J R Falck, Wei Shouzou, Jorge H. Capdevila

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Objectives: Epoxygenase metabolites produced by the kidney affect renal blood flow and tubular transport function and 11,12-epoxyeicosatrienoic acid (11,12-EET) has been putatively identified as an endothelium-derived hyperpolarizing factor. The current studies were performed to determine the influence of 11,12-EET on the regulation of afferent arteriolar diameter in angiotensin II-infused hypertensive rats. Materials and methods: Male Sprague-Dawley rats received angiotensin II (60 ng/min) or vehicle via an osmotic minipump. Angiotensin II-infused hypertensive and vehicle-infused normotensive rats were studied for 2 weeks following implantation of the minipump. Renal microvascular responses to the sulfonimide analog of 11,12-EET (11,12-EET-SI) and angiotensin II were observed utilizing the in-vitro juxtamedullary nephron preparation. Renal cortical epoxygenase enzyme protein levels were quantified by Western blot analysis. Renal microvessels were also isolated and epoxygenase metabolite levels measured by negative ion chemical ionization (NICI)/gas chromatography-mass spectroscopy. Results: Systolic blood pressure averaged 118 ± 2 mmHg prior to pump implantation and increased to 185 ± 7 mmHg in rats infused with angiotensin II for 2 weeks. Afferent arteriolar diameters of 2-week normotensive animals averaged 22 ± 1 μm. Diameters of the afferent arterioles were 17% smaller in hypertensive rats (P < 0.05); however, arterioles from both groups responded to 11,12-EET-SI (100 nmol) with similar 15-17% increases in diameter. As we previously demonstrated, the afferent arteriolar reactivity to angiotensin II was enhanced in angiotensin II-infused animals. Interestingly, elevation of 11,12-EET-SI levels to 100 nmol reversed the enhanced vascular reactivity to angiotensin II associated with angiotensin II hypertension. Renal microvascular EET levels were not different between groups and averaged 81 ± 9 and 87 ± 13 pg/mg per 30 min in normotensive and hypertensive animals, respectively. Renal cortical microsomal levels of the epoxygenase CYP2C23 and CYP2C11 proteins were also similar in normotensive and angiotensin II hypertensive rats. Conclusions: Taken together, these data support the concept that renal microvascular 11,12-EET activity and levels may not properly offset the enhanced angiotensin II renal vasoconstriction during angiotensin II hypertension.

Original languageEnglish (US)
Pages (from-to)983-992
Number of pages10
JournalJournal of Hypertension
Volume19
Issue number5
DOIs
StatePublished - 2001

Fingerprint

Angiotensin II
Hypertension
Kidney
Arterioles
11,12-epoxy-5,8,14-eicosatrienoic acid
Blood Pressure
Renal Circulation
Nephrons
Microvessels
Vasoconstriction
Gas Chromatography
Endothelium
Blood Vessels
Sprague Dawley Rats
Mass Spectrometry
Proteins
Western Blotting
Ions

Keywords

  • Cytochrome P450 metabolites
  • Endothelium-derived hyperpolarizing factor (EDHF)
  • Epoxyeicosatrienoic acid
  • Hypertension
  • Kidney

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Cite this

Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. / Imig, John D.; Zhao, Xueying; Falck, J R; Shouzou, Wei; Capdevila, Jorge H.

In: Journal of Hypertension, Vol. 19, No. 5, 2001, p. 983-992.

Research output: Contribution to journalArticle

@article{1b2876c6a097463e823b372befd6db62,
title = "Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid",
abstract = "Objectives: Epoxygenase metabolites produced by the kidney affect renal blood flow and tubular transport function and 11,12-epoxyeicosatrienoic acid (11,12-EET) has been putatively identified as an endothelium-derived hyperpolarizing factor. The current studies were performed to determine the influence of 11,12-EET on the regulation of afferent arteriolar diameter in angiotensin II-infused hypertensive rats. Materials and methods: Male Sprague-Dawley rats received angiotensin II (60 ng/min) or vehicle via an osmotic minipump. Angiotensin II-infused hypertensive and vehicle-infused normotensive rats were studied for 2 weeks following implantation of the minipump. Renal microvascular responses to the sulfonimide analog of 11,12-EET (11,12-EET-SI) and angiotensin II were observed utilizing the in-vitro juxtamedullary nephron preparation. Renal cortical epoxygenase enzyme protein levels were quantified by Western blot analysis. Renal microvessels were also isolated and epoxygenase metabolite levels measured by negative ion chemical ionization (NICI)/gas chromatography-mass spectroscopy. Results: Systolic blood pressure averaged 118 ± 2 mmHg prior to pump implantation and increased to 185 ± 7 mmHg in rats infused with angiotensin II for 2 weeks. Afferent arteriolar diameters of 2-week normotensive animals averaged 22 ± 1 μm. Diameters of the afferent arterioles were 17{\%} smaller in hypertensive rats (P < 0.05); however, arterioles from both groups responded to 11,12-EET-SI (100 nmol) with similar 15-17{\%} increases in diameter. As we previously demonstrated, the afferent arteriolar reactivity to angiotensin II was enhanced in angiotensin II-infused animals. Interestingly, elevation of 11,12-EET-SI levels to 100 nmol reversed the enhanced vascular reactivity to angiotensin II associated with angiotensin II hypertension. Renal microvascular EET levels were not different between groups and averaged 81 ± 9 and 87 ± 13 pg/mg per 30 min in normotensive and hypertensive animals, respectively. Renal cortical microsomal levels of the epoxygenase CYP2C23 and CYP2C11 proteins were also similar in normotensive and angiotensin II hypertensive rats. Conclusions: Taken together, these data support the concept that renal microvascular 11,12-EET activity and levels may not properly offset the enhanced angiotensin II renal vasoconstriction during angiotensin II hypertension.",
keywords = "Cytochrome P450 metabolites, Endothelium-derived hyperpolarizing factor (EDHF), Epoxyeicosatrienoic acid, Hypertension, Kidney",
author = "Imig, {John D.} and Xueying Zhao and Falck, {J R} and Wei Shouzou and Capdevila, {Jorge H.}",
year = "2001",
doi = "10.1097/00004872-200105000-00020",
language = "English (US)",
volume = "19",
pages = "983--992",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid

AU - Imig, John D.

AU - Zhao, Xueying

AU - Falck, J R

AU - Shouzou, Wei

AU - Capdevila, Jorge H.

PY - 2001

Y1 - 2001

N2 - Objectives: Epoxygenase metabolites produced by the kidney affect renal blood flow and tubular transport function and 11,12-epoxyeicosatrienoic acid (11,12-EET) has been putatively identified as an endothelium-derived hyperpolarizing factor. The current studies were performed to determine the influence of 11,12-EET on the regulation of afferent arteriolar diameter in angiotensin II-infused hypertensive rats. Materials and methods: Male Sprague-Dawley rats received angiotensin II (60 ng/min) or vehicle via an osmotic minipump. Angiotensin II-infused hypertensive and vehicle-infused normotensive rats were studied for 2 weeks following implantation of the minipump. Renal microvascular responses to the sulfonimide analog of 11,12-EET (11,12-EET-SI) and angiotensin II were observed utilizing the in-vitro juxtamedullary nephron preparation. Renal cortical epoxygenase enzyme protein levels were quantified by Western blot analysis. Renal microvessels were also isolated and epoxygenase metabolite levels measured by negative ion chemical ionization (NICI)/gas chromatography-mass spectroscopy. Results: Systolic blood pressure averaged 118 ± 2 mmHg prior to pump implantation and increased to 185 ± 7 mmHg in rats infused with angiotensin II for 2 weeks. Afferent arteriolar diameters of 2-week normotensive animals averaged 22 ± 1 μm. Diameters of the afferent arterioles were 17% smaller in hypertensive rats (P < 0.05); however, arterioles from both groups responded to 11,12-EET-SI (100 nmol) with similar 15-17% increases in diameter. As we previously demonstrated, the afferent arteriolar reactivity to angiotensin II was enhanced in angiotensin II-infused animals. Interestingly, elevation of 11,12-EET-SI levels to 100 nmol reversed the enhanced vascular reactivity to angiotensin II associated with angiotensin II hypertension. Renal microvascular EET levels were not different between groups and averaged 81 ± 9 and 87 ± 13 pg/mg per 30 min in normotensive and hypertensive animals, respectively. Renal cortical microsomal levels of the epoxygenase CYP2C23 and CYP2C11 proteins were also similar in normotensive and angiotensin II hypertensive rats. Conclusions: Taken together, these data support the concept that renal microvascular 11,12-EET activity and levels may not properly offset the enhanced angiotensin II renal vasoconstriction during angiotensin II hypertension.

AB - Objectives: Epoxygenase metabolites produced by the kidney affect renal blood flow and tubular transport function and 11,12-epoxyeicosatrienoic acid (11,12-EET) has been putatively identified as an endothelium-derived hyperpolarizing factor. The current studies were performed to determine the influence of 11,12-EET on the regulation of afferent arteriolar diameter in angiotensin II-infused hypertensive rats. Materials and methods: Male Sprague-Dawley rats received angiotensin II (60 ng/min) or vehicle via an osmotic minipump. Angiotensin II-infused hypertensive and vehicle-infused normotensive rats were studied for 2 weeks following implantation of the minipump. Renal microvascular responses to the sulfonimide analog of 11,12-EET (11,12-EET-SI) and angiotensin II were observed utilizing the in-vitro juxtamedullary nephron preparation. Renal cortical epoxygenase enzyme protein levels were quantified by Western blot analysis. Renal microvessels were also isolated and epoxygenase metabolite levels measured by negative ion chemical ionization (NICI)/gas chromatography-mass spectroscopy. Results: Systolic blood pressure averaged 118 ± 2 mmHg prior to pump implantation and increased to 185 ± 7 mmHg in rats infused with angiotensin II for 2 weeks. Afferent arteriolar diameters of 2-week normotensive animals averaged 22 ± 1 μm. Diameters of the afferent arterioles were 17% smaller in hypertensive rats (P < 0.05); however, arterioles from both groups responded to 11,12-EET-SI (100 nmol) with similar 15-17% increases in diameter. As we previously demonstrated, the afferent arteriolar reactivity to angiotensin II was enhanced in angiotensin II-infused animals. Interestingly, elevation of 11,12-EET-SI levels to 100 nmol reversed the enhanced vascular reactivity to angiotensin II associated with angiotensin II hypertension. Renal microvascular EET levels were not different between groups and averaged 81 ± 9 and 87 ± 13 pg/mg per 30 min in normotensive and hypertensive animals, respectively. Renal cortical microsomal levels of the epoxygenase CYP2C23 and CYP2C11 proteins were also similar in normotensive and angiotensin II hypertensive rats. Conclusions: Taken together, these data support the concept that renal microvascular 11,12-EET activity and levels may not properly offset the enhanced angiotensin II renal vasoconstriction during angiotensin II hypertension.

KW - Cytochrome P450 metabolites

KW - Endothelium-derived hyperpolarizing factor (EDHF)

KW - Epoxyeicosatrienoic acid

KW - Hypertension

KW - Kidney

UR - http://www.scopus.com/inward/record.url?scp=0035024260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035024260&partnerID=8YFLogxK

U2 - 10.1097/00004872-200105000-00020

DO - 10.1097/00004872-200105000-00020

M3 - Article

VL - 19

SP - 983

EP - 992

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 5

ER -